Abstract
The meta-analysis of randomized trials indicated a significant survival benefit when GEM was either combined with platinum analogs or fluoropyrimidines. Based on a preliminary subgroup analysis (representing 38% of all patients included in this meta-analysis), pancreatic cancer patients with a good PS appear to benefit from GEM-based cytotoxic combinations, whereas patients with a poor PS seem to have no survival benefit from combination chemotherapy.
Keywords
MedicineGemcitabineInternal medicinePemetrexedIrinotecanHazard ratioOncologyRandomized controlled trialPancreatic cancerChemotherapyMeta-analysisCombination chemotherapySurgical oncologyCancerSurgeryConfidence intervalCisplatinColorectal cancer
Affiliated Institutions
Related Publications
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefi...
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
The panel concludes that decisions regarding adjuvant hormonal therapy should be based on the presence of hormone receptor protein in tumor tissues. Adjuvant hormonal therapy sh...
Publication Info
- Year
- 2008
- Type
- review
- Volume
- 8
- Issue
- 1
- Pages
- 82-82
- Citations
- 425
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
425
OpenAlex
Cite This
Volker Heinemann,
Stefan Boeck,
Axel Hinke
et al.
(2008).
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
BMC Cancer
, 8
(1)
, 82-82.
https://doi.org/10.1186/1471-2407-8-82
Identifiers
- DOI
- 10.1186/1471-2407-8-82